Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad538 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Ann-Elin Meling Stokland und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Stavanger University Hospital, 4011 Stavanger, Norway. Hauptthemen laut MEDLINE: Graves Disease, Graves Ophthalmopathy, Hypothyroidism. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Foundation, Health Authorities of Western Norway, Stavanger University Hospital.
Abstract (Originalsprache)
Context
Graves disease (GD) is a leading cause of hyperthyroidism. Detailed investigations and predictors of long-term outcomes are missing.
Objective
This work aimed to investigate the outcomes in GD 25 years after initiating antithyroid drug treatment, including disease course, clinical and biochemical predictors of relapse, and quality of life.
Methods
A retrospective follow-up was conducted of GD patients that participated in a randomized trial from 1997 to 2001. Demographic and clinical data were obtained from medical records and questionnaires. Biobank samples were analyzed for inflammatory biomarkers and compared with age- and sex-matched healthy individuals.
Results
We included 83% (182/218) of the patients from the original study. At the end of follow-up, normal thyroid function was achieved in 34%. The remaining had either active disease (1%), spontaneous hypothyroidism (13%), or had undergone ablative treatment with radioiodine (40%) or thyroidectomy (13%). Age younger than or equal to 40 years, thyroid eye disease (TED), smoking, and elevated levels of interleukin 6 and tumor necrosis factor receptor superfamily member 9 (TNFRS9) increased the risk of relapsing disease (odds ratio 3.22; 2.26; 2.21; 1.99; 2.36). At the end of treatment, CD40 was lower in patients who maintained normal thyroid function (P = .04). At the end of follow-up, 47% had one or more autoimmune diseases, including vitamin B12 deficiency (26%) and rheumatoid arthritis (5%). GD patients who developed hypothyroidism had reduced quality of life.
Conclusion
Careful lifelong monitoring is indicated to detect recurrence, hypothyroidism, and other autoimmune diseases. Long-term ATD treatment emerges as a beneficial first-line treatment option, especially in patients with young age at onset or presence of TED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Stavanger University Hospital, 4011 Stavanger, Norway.
- Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
- Department of Research, Stavanger University Hospital, 4011 Stavanger, Norway.
- Department of Medicine, Haugesund Hospital, 5528 Haugesund, Norway.
- Department of Ophthalmology, Haukeland University Hospital, 5021 Bergen, Norway.
- Department of Endocrinology and Metabolism, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
ORCID-Profile: Ann-Elin Meling Stokland, Bjørn Gunnar Nedrebø, Kristian Løvås, Eystein Sverre Husebye
Förderung
- Novo Nordisk Foundation
- Health Authorities of Western Norway
- Stavanger University Hospital
- Norwegian Thyroid Patient Organization
- Health
- Western
Zitieren
APA
Meling Stokland, A. E., Austdal, M., Nedrebø, B. G., Carlsen, S., Hetland, H. B., Breivik, L., Ueland, H. O., Watt, T., Cramon, P. K., Løvås, K., Husebye, E. S., & Ueland, G. Å. (2024). Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad538
Vancouver
Meling Stokland AE, Austdal M, Nedrebø BG, Carlsen S, Hetland HB, Breivik L, et al. Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad538
BibTeX
@article{MelingStokland2024,
author = {Meling Stokland, Ann-Elin and Austdal, Marie and Nedrebø, Bjørn Gunnar and Carlsen, Siri and Hetland, Hanne Brit and Breivik, Lars and Ueland, Hans Olav and Watt, Torquil and Cramon, Per Karkov and Løvås, Kristian and Husebye, Eystein Sverre and Ueland, Grethe Åstrøm},
title = {Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad538}
}
EUVIMED